New Advances in Pharmacologic and Non-pharmacologic Therapy in Heart Failure and Heart Transplant

Dear Colleagues,

In recent years, treatment strategies for patients with heart failure have expanded, with new pharmacological (sacubitril/valsartan, SGLT2-i, vericiguat, omecamtiv mecarbil, ferric carboxymaltose) and non-pharmacological (cardiac contractility modulation, baroreceptor stimulation) options becoming available.

Despite these advances, the mortality and morbidity of heart failure patients are still high. In the upcoming ESC 2021 guidelines for the diagnosis and treatment of acute and chronic heart failure, the current challenge is to develop targeted therapies according to the etiology (e.g., amyloidosis, peripartum cardiomyopathy, inflammatory dilated cardiomyopathy) and the clinical phenotype of the patient (renal failure, bradycardia, low arterial pressure) and to the presence of comorbidities (iron deficiency, sleep-disordered breathing, diabetes). This tailored approach aims to prevent functional deterioration and to reduce morbidity and mortality.

Heart transplantation is the gold standard surgical approach to treating advanced heart failure. Recent advances have attempted to expand the pool of donor hearts; ameliorate the heart transplantation allocation policy; and better manage antibody sensitization.

This Special Issue aims to highlight new opportunities for improved treatments for heart failure and heart transplant patients.

Dr. Daniele Masarone
Dr. Carlo Lombardi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.